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ABSTRACT
The aim of this study was to investigate markers of inflammation and oxidative stress in the cor-
pus cavernosum (CC) and to compare levels of inflammatory markers recorded in CC to venous
blood from the arm to examine the potential impact of inflammatory parameters on erectile
function and endothelial dysfunction in vitro. Ninety-seven patients with no complaint of erectile
dysfunction (ED) at inclusion were prospectively included and completed the Erectile Function
domain of the IIEF questionnaire. Several parameters, including lipids, MPO-dependent oxidised
LDL (Mox-LDL), IL-8, IL-18, were measured. After RNA extraction, the expression of eNOS was ana-
lysed. A paired t-test was used for comparisons between arm and CC blood results. A two-way
ANOVA was used to estimate the effects of IL-18 and IL-8 on the IIEF score. Mean patient age
was 59±14.5 years. IL-18, Mox-LDL, and Mox-LDL/ApoB levels were significantly increased in CC
compared to arm blood. The IIEF score was correlated with IL-18 levels in the venous blood
(R¼0.31, p¼ .003) and in the CC (R¼0.37, p¼ .004) and with IL-8 (R¼0.31, p¼ .009 and
R¼0.28, respectively, p¼ .02). There was a significant effect with the IL-18 on IIEF potentiated
by high serum IL-8 concentrations. IL-18 and Mox-LDL significantly decreased eNOS mRNA
expression in human aortic endothelial cell line (HAEC). These preliminary results address the
importance of inflammation in the CC and highlight a difference in marker concentrations
between venous and CC blood. However, they do not show any difference in terms of clinical
erectile score predictivity. Involvement of inflammatory cytokines isolated in CC in the genesis of
ED requires further studies.
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Introduction
Erectile dysfunction (ED) is a common disorder where
oxidative stress impairs endothelial function leading
to the development of ED and cardiovascular diseases
(CVD) [1]. Its incidence increases with age, affecting
the quality of sexual and emotional life of men and
their partners [2]. ED is mainly of vascular origin and
is linked to several risk factors that are shared with
atherosclerosis, including being overweight, smoking,
physical inactivity, and lipid disorders responsible for
oxidative stress [3,4]. The link between these risk fac-
tors appears to be endothelial dysfunction.
Endothelial dysfunction is thus the common denomin-
ator of CVD and ED.
Endothelial cells of the corpus cavernosum (CC) con-
tribute to the production of nitric oxide (NO), which has
a major role in maintaining erectile function. NO stimu-
lates the formation of cyclic GMP (cGMP), which leads
to smooth muscle relaxation, facilitating erection. An
anomaly in the NO/cGMP pathway may lead to the
development of ED [5]. ED is considered as a clinical
manifestation of functional and structural vascular
abnormalities affecting the penile circulation and may
evolve as part of systemic CVD. Indeed, oxidative stress
and inflammation, both initiating CVD, can induce
endothelial dysfunction with a reduction in the biosyn-
thesis of NO. The role of lipids in the formation and evo-
lution of the atherosclerotic plaque is also well
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established [6]. The development of the atherosclerotic
plaque involves the intervention of macrophages,
recruitment of lymphocytes, and accumulation of oxi-
dised low-density lipoproteins (LDL). Myeloperoxi-dase
(MPO), an enzyme found in neutrophils and monocytes,
is partly responsible for the formation of oxidised LDL
and is considered as an inducer of endothelial dysfunc-
tion and a cardiovascular risk factor [7,8]. LDL oxidised
by MPO (Mox-LDL) were shown to be present in the CC
of patients with ED of vascular origin [9]. In vitro, Mox-
LDL induce an inflammatory response by increasing the
production of cytokines, such as interleukin-8 (IL-8), by
endothelial cells and decreasing the concentration of
cGMP, the second mediator involved in the relaxation
of smooth muscle cells, the major factor in the physio-
logical mechanism of erection [10,11].
ED has also been shown to be associated with other
circulating inflammatory parameters, such as high sensi-
tivity C-reactive protein (hs-CRP), IL-1b and tumour
necrosis factor (TNF)-a [12]. IL-18 is a proatherogenic
cytokine that amplifies the inflammatory cascade by
stimulating the expression of other proinflammatory
cytokines, such as IL-8 and adhesion molecules.
Chandrasekar et al. demonstrated that IL-18 activates
both intrinsic and extrinsic proapoptotic signalling
pathways, inducing endothelial cell death or apoptosis
[13]. A recent meta-analysis reported that circulating IL-
18 is prospectively and independently associated with
cardiovascular disease risk [14].
The primary objective of this study was to investigate
the relationship between markers of inflammation, in
particular IL-18, MPO, and Mox-LDL in the CC and erect-
ile function score. Secondary aims were to compare the
levels of inflammatory markers recorded in CC and per-
ipheral blood and to examine, using an endothelial cell
line, the potential impact of inflammatory parameters
(Mox-LDL and IL-18) in endothelial dysfunction and
eNOS mRNA expression in vitro.
Materials and methods
Patient selection and clinical characterisation
After approval by the Ethics Committee of Erasme-ULB
hospital, 97 patients aged over 18 years (20–84 years)
with no complaints of clinical ED, who were hospitalised
in the Urology Department of Erasme-ULB hospital for
endoscopic procedures, were prospectively included in
the study between January and May 2010. All subjects
signed an informed consent form specifying the pur-
pose of the study and methods of blood sampling.
On inclusion, the following data were recorded: body
mass index (BMI), comorbidities (diabetes, hypertension,
ischemic cardiomyopathy, dyslipidaemia, smoking his-
tory, depression) and medications. The part of the
“International Index of Erectile Function” questionnaire
corresponding to the five questions devoted to the
erectile function domain score (IIEF-EF) was completed
by each participant. A lower score corresponds normally
to a higher severity of ED in clinical setting.
Under general or spinal anaesthesia, and before
starting each procedure (including bladder catheter
insertion if any), a venous blood sample (8–10ml) was
collected and placed in a dry tube and a citrate tube,
followed by a nonporous sample of about 4–8ml from
the CC using an 18-gauge needle. The samples were
then centrifuged for 10min at 3000g and the super-
natant collected and frozen. Blood tests were per-
formed at the Laboratory of Experimental Medicine of
the University Hospital of Charleroi, site A. Vesale, Unit
222, ULB. The following parameters were measured:
Total plasma testosterone, C-reactive protein (CRP),
blood glucose, glycosylated haemoglobin (HbA1c), total
cholesterol, triglycerides, HDL-cholesterol (standard
laboratory techniques PLC), and adiponectin.
LDL-cholesterol levels were calculated using the
Friedewald formula (LDL-c¼ TCHDL-c TG/5 (mg/
dl)). The antibodies used for the measurements of Mox-
LDL have been fully characterised previously [15]. The
MPO content in plasma was measured using ELISA tests
(ELIZEN MPO, Zentech SA, Belgium) [16].
Cytokine quantification
IL-8 and IL-18 serum concentrations were quantified
using an ELISA test (Becton DickinsonVR , Franklin Lakes,
NJ, USA).
Incubation of endothelial cells with native and
oxidised LDL and cytokines
Human aortic endothelial cell line (HAEC) (Lonza), a
human aortic endothelial primary cell obtained at pas-
sage 2. These cells are very well characterised and
were cultured in Endothelial Cell Basal Medium-two
and the following growth supplements: hydrocorti-
sone, basic fibroblast growth factor, vascular endothe-
lial growth factor, insulin-like growth factor, ascorbic
acid, heparin, FBS, human epidermal growth factor,
gentamicin, amphotericin B (Lonza). Experiments were
performed at passage 4 where native LDL and Mox-
LDL (100 mg/ml), IL-18 (250 pg/ml) and TNF-a
(10 ng/ml), sterilised by filtration through a 0.22-mm
membrane (Millipore), were added to the culture
medium and incubated with the endothelial cells for
24 hours at 37 C under 5% CO2. The experiments were
performed in triplicate.
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Isolation and oxidation of lipoproteins
Low-density lipoproteins were isolated from pooled
plasma from healthy males using sequential ultracentri-
fugation [17]. LDL fractions (d¼ 1.019 1.063) were
stored at 4 C in the dark. Prior to oxidation, LDL was
gel filtered (PD-10 column, Pharmacia) and 1.6mg of
LDL was oxidised at 37 C in the presence of 2.6 chlori-
nating units of recombinant MPO [18] and 1mmol/L
H2O2 in PBS at pH¼ 6.5 for 5min to form fraction B of
MPO-dependent oxidised LDL (Mox-LDL, 15). The reac-
tion was stopped on ice. The concentration of LDL in
samples was determined according to the Lowry
method.
Characterisation of Mox-LDL
Mox-LDL have been characterised previously [10,15,19].
However, native or Mox-LDL were routinely controlled
by loading them onto a 1% agarose gel (Beckman).
After electrophoresis (120V, 30min) in barbital buffer,
fixation was performed in a solution of 30% methanol
20% acetic acid. The gel was stained in Paragon blue
stain solution and destaining was carried out in a solu-
tion of 5% acetic acid. The presence of a characteristic
band corresponding to Mox-LDL allowed us to verify
that the oxidation process succeeded as Mox-LDL has
increased electrophoretic mobility compared to LDL.
RNA extraction
After treatment, cells were washed with cold PBS and
total RNA was extracted using the RNeasy kit, according
to the manufacturer’s protocol (Qiagen, Hilden,
Germany). Extracts were stored at 80 C.
Gene expression analysis
RNA concentration and integrity were evaluated with a
NanoDrop spectrophotometer (Thermo Scientific,
Waltham, MA, USA). RNA (1 mg) was reverse transcribed,
using a Transcriptor High Fidelity cDNA Synthesis Kit
(Roche). Real-time qPCR assays were performed with a
Light Cycler 480 (Roche, Basel, Switzerland), using
400 ng of cDNA per reaction and SYBR-Green dye. The
expression of endothelial NO synthase (eNOS) was
assessed using the following primers obtained from
Merck (Darmstadt, Germany; formerly Sigma-Aldrich, St
Louis, MO, USA): Forward primer – AGGAACCTGTGTG-
ACCCTCA; reverse primer – CGAGGTGGTCCGGGTATCC.
The 1.5.0 SP4 software from Light Cycler 480 was used
for calculations. The relative level of expression was
measured by the comparative CT (DDCT) method with
HMBS (forward primer: AAGTGCGAGCCAAGGACCAGGA;
reverse primer: CAGCGATGCAGCGAAGCAGAGT), GAPDH
(forward primer: ACCCACTCCTCCACCTTTGAC; reverse
primer: GTCCACCACCCTGTTGCTGTA) and 18S (forward
primer: TGGTGCATGGCCGTTCT; reverse primer: TAGT-
TAGCATGCCAGAGTCTCGTT) genes as references.
Statistical analysis
Sigma Stat 3.0 software SPSS (San Jose, CA, USA)
was used for statistical analysis. Differences were
considered statistically significant with a two-tailed
p< .05. Comparisons between arm and CC blood
results were made using a Wilcoxon’s signed rank
test. Univariate analyses were depicted by Pearson’s
coefficient. Several models of multiple linear regres-
sion analysis were tested including nine variables of
interest. The standardised regression coefficients and
p value is reported for each model. For multiple lin-
ear correlations some values were transformed into
“log” to respect homoscedasticity.
Results
Clinical characteristics and univariate analysis
Clinical characteristics and biological parameters, known
to be important in ED or CVD, were recorded from the
patients as shown in Table 1. No clinically relevant car-
diovascular diseases nor arthritis were registered.
Despite no complaint of ED, the patients admitted for
endoscopy had a mean IIEF-EF score of 15 þ/ 9.5,
reflecting a wide variation of interpretation from no to
severe erectile dysfunction. IL-18, Mox-LDL and Mox-
LDL/ApoB levels were significantly higher in the CC
blood compared to the arm. It is noteworthy that the
IL-18 levels are higher than the values reported in litera-
ture for healthy subjects [20]. In contrast, adiponectin,
ApoB and ApoA-1 levels were significantly lower in
blood from the CC than from the arm. No difference
was observed in IL-8 levels. Haematocrits were com-
pared between arm blood and CC with no difference
suggesting, as a valid argument, the absence of an hae-
modilution or concentration phenomenon (n¼ 20,
p¼ .45, Supplement data 1).
Univariate analysis showed that the IIEF score was
negatively correlated with IL-18 levels in the arm
(R¼0.31, p¼ .003) and in the CC (R¼0.37, p¼ .004,
Figure 1). The IIEF was also negatively correlated with
IL-8 in the arm (R¼0.31, p¼ .009) and in the CC
(R¼0.28, p¼ .02). In contrast, there was no correlation
between BMI and IL-18 levels in the arm and CC (p¼ .37
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and .66, respectively) nor between IL-18 and glycemia
or HbA1c (p¼ .7 and .1, respectively).
Table 2 shows correlations between arm and CC for
the measured parameters. The IL-8 in arm is well corre-
lated with the IL-8 in CC (R¼ 0.6; p< .001). IL-18 in arm
is also well correlated with IL-18 in CC (R¼ 0.74;
p< .001). Globally, a good correlation between blood
parameters and CC parameters are observed.
Multilinear regression analysis
We investigated whether an explanatory correlation
could be found between any of the analysed parame-
ters using a multivariate analysis. We ran a first model
(Model-1, Table 3) in which the IIEF score was the
dependent variable and age, BMI, smoking habit, dia-
betes, IL-18, IL-8, adiponectin, Mox-LDL, and testoster-
one in blood from the arm were independent variables.
Significant associations were found between IIEF and IL-
18, IL-8 and age but not between IIEF and any other
parameters. We ran a second model (Model-2, Table 3)
using the same parameters but measured in CC blood.
The associations between the IIEF and IL-18, IL-8 and
age were confirmed. The r2 values for the two models
were 0.493 (arm) and 0.497 (CC), suggesting that nearly
50% of the variability in the IIEF in this group could be
explained by these variables, with IL-18 as the most
prominent explanatory variable.
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Figure 1. Correlation between IIEF score and IL-8 and IL-18 levels in arm and corpus cavernosum.
Table 1. Patient cohort characteristics.
Blood sampling site
N¼ 97 All Arm Corpus Cavernosum p value
IIEF-EF 19 (6–24)
Age (years) 61 (49–71)
BMI (kg/m2) 26 (24–29)
Diabetes 13 (13.4%)
Smokers 27 (28%)
Glycemia (mg/dl) 98 (87–111)
HbA1c (%) 5.7 (5.3–6.1)
Testosterone (ng/ml) 4 (3–5.4)
Adiponectin (pg/ml) 8137 (419–19218) 7476 (429–13968) <.001
IL-18 (pg/ml) 328 (267–430) 365 (286–508) <.001
IL-8 (pg/ml) 12.9 (9.4–19.7) 11.2 (8–19.7) .1
Mox-LDL (lg/ml) 5.4 (4.4–9.4) 10 (5.5–23.1) .001
MPO (mg/ml) 31 (20.8–60) 46.5 (25.6–95.9) .02
Mox-LDL/ApoB 103 7.1 (5.2–11) 11 (7–16) .005
Total cholesterol (mg/dl) 174 (149–209)
Triglycerides (mg/dl) 108 (69–131)
HDL-c (mg/dl) 47 (40–53)
ApoB (mg/dl) 80 (64–97) 77 (66–92) <.001
ApoA (mg/dl) 126 (110–144) 118 (109–139) <.001
p value: Wilcoxon’s Signed Rank test.
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We ran also two other multivariate models in inte-
grating an interaction term (multiplication between IL-8
and IL-18) in arm and CC, respectively (Model-3 and
Model-4, Table 4). When we introduce the interaction
term, this last one is preponderant in arm and in CC
models.
In vitro experiments
We performed in vitro experiments in order to investi-
gate putative molecular mechanisms supporting the
synergy between the two cytokines observed in the
clinical study. First, we assessed the direct effect of IL-18
on IL-8 expression. Indeed, HAEC cells in culture were
treated with concentrations within the physiologic
range of IL-18 for such a population of male patients
(250 pg/ml) [21,22]. No induction of IL-8 expression by
IL-18 stimulation could be detected. In contrast, IL-8
was stimulated by TNF-a, LDL, and Mox-LDL (Figure 2).
Unfortunately, the reverse experiment could not be per-
formed because HAEC cells constitutively express IL-8,
accumulating it in the culture medium. As no IL-18
could be detected in these conditions, it nevertheless
indicates that these IL-8 concentrations are not able to
trigger IL-18 expression by HAEC cells.
As endothelial function could be negatively
impacted by vascular inflammatory markers on NO
activity, the eNOS expression was monitored in HAEC
cells in culture treated with IL-18 (Figure 3). IL-18
administration caused a decrease in eNOS mRNA
expression as also observed with Mox-LDL and TNF-a.
Discussion
CVD and ED share the same risk factors and they have
common denominators: oxidative stress and
Table 2. Correlations between arm and corpus cavernosum parameters.
R (p)
Adiponectin
arm
IL-8
arm
IL-18
arm
Mox-LDL
arm
Mox-LDL/ApoB
arm
Adiponectin CC 0.97 (<106)
IL-8 CC 0.6 (105)
IL-18 CC 0.74 (105)
Mox-LDL CC 0.82 (105)
Mox-LDL/ApoB CC 0.99 (<106)
Table 3. Multiple Linear regression, Model-1 (Arm) and
Model-2 (CC).
Arm Corpus Cavernosum
(n¼ 97)
Stand. Reg
Coefficient p value
Stand. Reg
Coefficient p value
R2¼ 0.493; p¼ .006 R2¼ 0.497; p¼ .005
Age 0.336 .02 0.318 .02
BMI 0.034 .84 0.004 .97
Smoking Habit 0.142 .34 0.296 .06
Diabetes 0.001 .99 0.011 .94
IL-18 0.326 .03 0.263 .04
IL-8 0.338 .05 0.348 .03
Adiponectin 0.85 .55 0.042 .76
Mox-LDL 0.061 .70 0.237 .10
Testosterone 0.081 .56 0.017 .91
IIEF is the dependent variable while independent variables are: Age, BMI,
smoking habit, diabetes, IL-18 (arm or CC), IL-8 (arm or CC), adiponectin
(arm or CC), myeloperoxidase-modified LDL (Mox-LDL, arm or CC),
testosterone.
Table 4. Multiple Linear regression, Model-3 (Arm) and
Model-4 (CC).
Arm Corpus Cavernous
(n¼ 97)
Stand. Reg
Coefficient p value
Stand. Reg
Coefficient p value
R2¼ 0.455; p¼ .005 R2¼ 0.503; p¼ .009
Age 0.206 .12 0.326 .02
BMI 0.144 .39 0.003 .98
Smoking Habit 0.021 .80 0.305 .06
Diabetes 0.076 .68 0.017 .92
IL-18 0.381 .11 0.162 .82
IL-8 0.167 .05 0.182 .83
IL-18xIL-8 0.237 .02 0.673 .01
Adiponectin 0.050 .55 0.035 .55
Mox-LDL 0.112 .40 0.222 .40
Testosterone 0.031 .76 0.036 .76
IIEF is the dependent variable while independent variables are: Age, BMI,
smoking habit, diabetes, IL-18 (arm or CC), IL-8 (arm or CC), interaction
factor (IL-8 IL-18 in arm or CC), adiponectin (arm or CC), myeloperoxi-
dase-modified LDL (Mox-LDL, arm or CC), testosterone.
Figure 2. No direct effect of IL-18 on IL-8 expression. HAEC
were exposed to Native LDL and Mox-LDL (100 mg/ml), IL-18
(250 pg/ml) and TNF-a (10 ng/ml) for 24 h. ANOVA <0.001,< 0.05 versus control, Bonferroni post-hoc test.
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inflammation leading to endothelial dysfunction.
However, ED is generally admitted as a predictive event
for more severe cardiovascular diseases [23,24]. But the
question remains whether the endothelial dysfunction
in CC is a reflect of the systemic vascular endothelial
dysfunction or a local effect. In this context, there are
few reports comparing oxidative stress and inflamma-
tion in peripheral venous blood (commonly used in
studies) and cavernosal blood. As we have demon-
strated the presence of Mox-LDL in CC blood from
patients with ED [9], we systematically measured Mox-
LDL in both compartments together with IL-18 and IL-8,
which have been associated with CVD and ED. Indeed,
proinflammatory cytokines such as IL-8 and IL-18 are
found at higher circulating concentrations in obese
patients with erectile and endothelial dysfunction [25].
In this study, a mean IIEF-EF score of 15þ/9.5 was
calculated in 97 patients admitted for endoscopy,
whose systematic questioning did not report a clinical
erectile problem, showing that an objective interpret-
ation of the score can be difficult for clinical evaluation
in some men. Nevertheless, we can notice a dispersion
of the scoring among the patient population, which
reinforce the correlation study between inflammatory
factors and IIEF-EF score.
Univariate and multivariate analysis showed that
IL-18 and IL-8, in combination or alone, were the best
explanatory parameters of the IIEF-EF score variation.
This observation was confirmed in peripheral and caver-
nosal blood. More importantly, the comparisons
between the cavernosal and peripheral venous blood
showed that IL-18, Mox-LDL and the Mox-LDL/ApoB
ratio (which is an estimation of the fraction of blood
MPO modified LDL) were significantly increased in the
CC, suggesting a local effect in CC. Interestingly, there
was no difference between haematocrits and IL-8 levels
in the arm or in CC blood, suggesting the absence of an
haemodilution or haemoconcentration phenomenon.
Several data in literature are in favour of a local effect
in CC. The capture antibody used for Mox-LDL reacts
only with LDL modified by the MPO/H2O2/Cl
 system
[15] and this allowed us to detect them in CC of
patients with ED [9]. We also showed that the mem-
brane-bound-nicotinamide-adenine-dinucleotide phos-
phate (NADPH) oxidase of endothelial cells plays a
central role in Mox-LDL generation [26]. Indeed, the O2

generated by membrane NADPH oxidase is the starting
substrate for generating hydrogen peroxide (H2O2), a
key substrate for MPO with regard to catalysing the pro-
duction of HOCl. It is the production of HOCl by MPO
that allows production of Mox-LDL. Moreover, an
increase in H2O2 in the CC compared to the cubital vein
has been reported by Yeni et al. [27]. Those observa-
tions may explain why Mox-LDLs were increased in CC
blood, suggesting also a local inflammatory phenom-
enon despite the fact that there was no correlation with
the IIEF score.
Diabetic patients with ED have been shown to have
increased endothelial apoptotic cell density in the CC
[28]. IL-18 is expressed secondarily to inflammasome
induction, which is mostly restricted to monocytes/mac-
rophages. Previously, we observed that Mox-LDL could
trigger an inflammasome on monocytes/macrophages
(unpublished data). These effects suggest that the
increase in IL-18 in the CC could be linked to the blood
monocytes/macrophages triggered by the increase in
Mox-LDL.
It is noteworthy that adiponectin was diminished
(þ/ 20%) in CC blood compared to the arm. Several
studies have reported endothelial protective effects of
adiponectin, such as suppression of apoptosis [29,30],
activation of eNOS and an increase in NO production. In
our cohort, no correlation between adiponectin and the
IIEF score was observed. However, we cannot exclude a
local loss of the protective function of adiponectin, act-
ing against the proapoptotic effect of IL-18.
NO plays a central role in vasodilation and erection.
HOCl-modified LDL [31] has been documented to
induce eNOS mislocalisation, leading to a decrease in
NO production. Previously, we also showed that Mox-
LDL decreased cGMP in endothelial cells. In the current
study, our in vitro experiments showed that IL-18 and
Mox-LDL significantly decreased eNOS mRNA expres-
sion in endothelial cells by þ/ 25%. Indeed, erectile
and endothelial dysfunction may share some pathways
through a defect in nitric oxide activity. Interestingly,
IL-8 secretion was not increased by IL-18 in vitro in
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Figure 3. HAEC were exposed to Native LDL and Mox-LDL
(100 mg/ml), IL-18 (250 pg/ml) and TNF-a (10 ng/ml) for 24 h.
Three independent experiments were performed in triplicate.
ANOVA <0.001, < 0.05 versus control, Bonferroni post-hoc
test.
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contrast to LDL, Mox-LDL and TNF-a (Figure 2).
One explanation for this statistical interaction could be
that the IL-8 level reflects a dysfunctional status of the
endothelial cells, which may be more reactive than the
biological effect of IL-18.
One major limitation of this study is that the design
does not allow us to emphasise a clear role for IL-8 and
IL-18 in ED. Oxidative stress and IL-18 are increased in
CC of patients with no complaint of ED. Even if oxida-
tive stress markers are increased in the corpus caverno-
sum, there is no difference in terms of erectile
dysfunction prediction between the arm and corpus
cavernosum potentially due to the fact that the popula-
tion included patients with a low morbidity condition.
Moreover, we cannot exclude an influence of the con-
centrations of inflammatory markers in CC on their con-
centrations in arm the impact of the inflammation
markers is therefore difficult to assess with certainty
and there is always space for ED evaluation and inter-
pretation. This state could be a physiological condition
and deserves continued consideration to explore levels
in patients with complaints of ED with or without car-
diovascular comorbidities. In addition, the same investi-
gation could be carried out with patients complaining
for clinical ED by vascular evaluation of ED with colour
penile Doppler which aims at identifying contributing
arterial and venous abnormalities [32]. Indeed, impaired
endothelial function is considered as predictive of poor
cardiovascular health and can be measured via several
peripheral methods in ED patients to identify those
patients with higher cardiovascular risk [33]. This is
emphasised by Vardi et al. who reported evidence of
focal impairment of the endothelial function in penis of
ED patients [34] without the need for significant periph-
eral disease.
Conclusions
The endothelium plays a key role in maintaining tone
and vascular integrity through the synthesis and release
of NO. The decrease in NO production by oxidative
stress, inflammation, and endothelial cell apoptosis con-
tributes to the vascular aetiology of ED.
This study highlights the importance of inflammation
in the CC compared to the peripheral venous blood and
shows an interaction of inflammatory markers, such as
IL-8 and IL-18, with the clinical erectile score reported
by patients. These preliminary results need to be con-
firmed before to conclude to a potential use in clinical
evaluation. Moreover, the difference in inflammatory
marker concentrations in the venous blood and the CC
highlights the importance of the site of the blood sam-
ple and should be taken into account in future studies
with the difficulty and the inconvenience of cavernous
blood uptake. Our results also show the need to study
interactions among various blood parameters and
endothelial cells. In addition, the increase in inflamma-
tory markers (Mox-LDL and IL-18) in CC blood compared
to arm blood in patients with no clinical ED is in accord-
ance with the identification of ED as a sentinel symp-
tom for upcoming CVD and also the consequence of
local effect. A prospective study is needed including ED
patients with objective evaluation of endothelial dys-
function to identify men with vasculogenic ED at higher
risk for cardiovascular diseases.
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